Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Working Capital Changes: 2020-2024

Historic Other Working Capital Changes for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to $83.4 million.

  • Monte Rosa Therapeutics' Other Working Capital Changes rose 1295.92% to $110.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.7 million, marking a year-over-year increase of 172.32%. This contributed to the annual value of $83.4 million for FY2024, which is 66.76% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Other Working Capital Changes of $83.4 million as of FY2024, which was up 66.76% from $50.0 million recorded in FY2023.
  • Monte Rosa Therapeutics' 5-year Other Working Capital Changes high stood at $83.4 million for FY2024, and its period low was $704,000 during FY2021.
  • Over the past 3 years, Monte Rosa Therapeutics' median Other Working Capital Changes value was $50.0 million (recorded in 2023), while the average stood at $45.2 million.
  • In the last 5 years, Monte Rosa Therapeutics' Other Working Capital Changes crashed by 48.87% in 2021 and then spiked by 2,250.73% in 2023.
  • Monte Rosa Therapeutics' Other Working Capital Changes (Yearly) stood at $1.4 million in 2020, then tumbled by 48.87% to $704,000 in 2021, then spiked by 202.13% to $2.1 million in 2022, then skyrocketed by 2,250.73% to $50.0 million in 2023, then spiked by 66.76% to $83.4 million in 2024.